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Abstract
Background: Bacteriophages can be successfully applied to treat infections caused by antibiotic-
resistant bacteria. Until now no attempts have been undertaken to treat infections in
immunosuppressed patients with phages. In this work we investigated the prophylactic efficacy of
specific bacteriophages in CBA mice treated with cyclophosphamide (CP) and infected with
Staphylococcus aureus.
Results: High numbers of bacterial colony-forming units in the organs as well as elevated tumor
necrosis factor and interleukin-6 serum concentrations in CP-treated and S. aureus-infected mice
were significantly lowered upon application of phages. The phages markedly increased the
percentage of circulating neutrophils and immature cells from the myelocytic and lymphocytic
lineages in CP-treated, S. aureus-infected mice as well as of myelocytes and immature neutrophils
in the bone marrow. In addition, phages stimulated in such mice generation of specific agglutinins
against S. aureus.
Conclusion: Application of specific phages to immunosuppressed mice prior to infection with S.
aureus  proved very effective, suggesting a potential benefit of phage therapy in
immunocompromised patients experiencing bacterial infections.
Background
Phage therapy offers an excellent alternative to antibiotic
therapy of bacterial infections (reviewed by [1]). Despite
obvious efficacy in curing antibiotic-resistant infections it
is still considered as "experimental" although it used to be
a routine therapeutic approach to treat bacterial infections
before introduction of antibiotics into therapy in the first
half of the XXth century. In contrast to antibiotics, which
usually exhibit suppressive actions in relation to the
immune response and deplete physiological intestinal
microflora [2,3], the phage lytic action is highly selective.
Moreover, phages demonstrate some bystander effects,
beneficial to the function of the immune system such as:
normalization of cytokine production by blood cells iso-
lated from patients [4], acceleration of the neutrophil
turnover [5], and inhibition of both bacteria- and LPS-
induced respiratory burst by human blood phagocytes
[6,7]. A discovery that phages may limit metastasis of B16
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melanoma in mice [8] suggests a benefit of phage therapy
in patients with malignant diseases.
Effectiveness of phage therapy may be, however, limited
by several factors. Phage-resistant mutants has been
observed in many phage-bacteria systems in Gram-posi-
tive and Gram-negative microorganisms [9]. Antibodies
against bacteriophages may also appear during therapy
[10,11]. Host specificity is another limitation. Majority of
known bacteriophages are host-specific [12] and some are
strain-specific [13]. Therapeutic phage preparations are
mostly based on crude lyzates so they are not free from
culture media ingredients and bacterial intracellular com-
ponents including endotoxins. These agents are thought
to be the reason of the adverse effects of phage therapy
[14]. Lastly, a presence of lysogenic particles occurring in
majority of bacterial population may also create a prob-
lem. In these cells bacteriophage genom is integrated
within bacterial chromosome as prophage. Temperate
bacteriophages may carry host genes to other bacterial
cells and be responsible for horizontal gene transfer [15].
Nevertheless, despite all these limitations the phage ther-
apy remains an alternative in antibiotic-resistant infec-
tions.
Although the majority of studies on phage therapy have
been carried out on immunocompetent patients, there are
also data indicating that phages could be effective and safe
in immunocompromised individuals (for review see
[16]). Of particular importance are the results achieved in
immunocompromised cancer patients, which showed
that phages could cure different kinds of bacterial infec-
tions without causing any serious side effects [17], as well
as preliminary data obtained in a small group of renal
transplant recipients (for references see [18]). Interest-
ingly, phages may prolong mouse allograft survival,
which constitutes an important argument for the safety of
phage therapy in transplant recipients [19].
Although cyclosporine and steroids may not significantly
impair function of cells responsible for innate immunity
[20], some myeloablative agents like cyclophosphamide
(CP) can transiently deplete the neutrophil pool [21] ren-
dering a patient defenseless against infection. CP is widely
used for treatment of autoimmune diseases [22-24] and
leukemias [25]. The drug causes a profound, transient leu-
kopenia [26], it also suppresses humoral [27] as well as
cellular immune responses [28]. Although the neutrope-
nia is transient and leads later to mobilization of myelo-
poiesis [29], the impairment of the specific humoral
response, crucial for the development of adaptive immu-
nity to pathogens, is long-lasting [27]. Therefore, the aim
of this study was to evaluate effectiveness of prophylactic
phage administration to CP-immunosuppressed mice on
several parameters associated with innate and acquired
immune response to S. aureus such as: number of bacteria
in organs of infected mice, serum level of proinflamma-
tory cytokines, blood and bone marrow cell profile and
ability to generate specific antibody response to S. aureus.
In this work we convincingly demonstrate that adminis-
tration of specific phages prior to infection can compen-
sate the deficit of neutrophils in the clearance of S. aureus
from the organs of CP-treated and infected mice. Moreo-
ver, the phages regulated the levels of proinflammatory
cytokines and elicited mobilization of cells from both
myelocytic and lymphocytic lineages. Lastly, the applica-
tion of phages stimulated generation of specific antibod-
ies to S. aureus and to an unrelated antigen sheep red
blood cells.
Methods
Mice, strains and reagents
CBA male mice, 10–12 weeks-old, were purchased from
Ilkowice/Kraków, Poland. The mice had free access to
water and standard rodent laboratory chow. All protocols
were approved by the local ethics committee.
Staphylococcus aureus L strain was isolated from a 26-year
old patient A.L., suffering from pharyngitis. In vitro analy-
sis (antibiogram) revealed its sensitivity to the following
antibiotics: amikacin, ciprofloxacin, doxycycline, erythro-
mycin, gentamycin, clindamycin and methicillin. Unfor-
tunately, the antibiotic treatment was not effective so the
patient was subsequently subjected to successful phage
therapy. This is a typical S. aureus strain producing beta-
hemolysin. The lethal dose of this strain for CBA mice pre-
treated with 350 mg/kg b.w. of CP was 4 × 108 (LD100).
Both S. aureus strain and S. aureus A5/L bacteriophages are
deposited in the Bacteriophage Laboratory of the Institute
of Immunology and Experimental Therapy, Wrocław. The
preparation and purification of specific bacteriophages
were described by us elsewhere [30]. LPS contamination
of the phage preparation was negligible as determined by
Limulus amebocyte lysate (LAL) (1.8 E.U. per 106
phages). Cyclophosphamide (CP) was from ASTA Med-
ica, Frankfurt, Germany.
Treatment of mice with cyclophosphamide, S. aureus and 
bacteriophages
Mice were injected with CP (200 or 350 mg/kg b.w.) intra-
peritoneally (i.p.) as indicated in the figure legends. Bac-
teria were administered intravenously (i.v.), into lateral
tail vein, four days after CP, at a dose of 5 × 106/mouse.
Bacterial cell numbers were determined colorimetrically
at a wavelength of 600 nm according to previously pre-
pared standards. Virulent S. aureus A5/L bacteriophages
were administered i.p. 30 minutes before infection, at a
dose of 1 × 106/mouse. Control mice received 0.2 ml of
0.9% NaCl instead of bacteria and phages. In some exper-BMC Microbiology 2009, 9:169 http://www.biomedcentral.com/1471-2180/9/169
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imental protocols control mice were given phages or bac-
teria only.
Determination of S. aureus in the organs
Twenty four hours after infection, the mice were sacri-
ficed, the organs (spleens, livers and kidneys) were iso-
lated and homogenized using a plastic syringe piston and
a plastic screen, in sterile PBS (1 g of wet tissue per 25 ml
of PBS). Five- and fifty-fold dilutions of cell suspension
were applied onto Chapmann agar plates and incubated
overnight and the colony-forming units (CFU) were enu-
merated. The number of colonies was expressed as the
number of CFU per milligram of the organ.
Analysis of cell types in the circulating blood and bone 
marrow
Samples of blood were taken on day 0, just before admin-
istration of CP, 4 days after administration of CP, just
before administration of phages and bacteria (day 4) and
at 24 h following infection (day 5). The bone marrow was
isolated on days 0 and 5. Blood and bone marrow smears
were prepared and stained with May-Grünwald and
Giemsa reagents. The preparations were reviewed micro-
scopically by a histologist at 1000× magnification.
Determination of serum TNF-α and IL-6 levels
The activities of TNF-α and IL-6 in sera were determined
by bioassays using WEHI 164.13 and 7TD1 cell lines,
respectively [31,32].
Determination of serum antibody titer to S. aureus and 
sheep red blood cells (SRBC)
Mice were given CP (200 mg/kg b.w.). After four days the
mice were infected i.v. with S. aureus at a dose of 5 × 106/
mouse and administered i.p. A5/L phage (1 × 106/
mouse). 21 days later the mice were bled and the sera iso-
lated. Using a similar protocol mice were immunized with
0.2 ml of 10% SRBC i.p., one hour after infection with S.
aureus and the mice were bled on day 10 after immuniza-
tion. The agglutination test for measuring the titer of anti-
S. aureus antibodies was performed as follows: 50 μl of
two-fold sera dilutions were distributed in 96-well micro-
titer plates and 25 μl of 1% thermally-inactivated S. aureus
suspension was added. After 1 h incubation at room tem-
perature the agglutination was determined in a micro-
scope. The hemagglutination test was performed
analogously using 1% SRBC suspension as antigen.
Statistical analysis
The results of one representative experiment, out of three
performed, were shown. For statistical evaluation of the
data, analysis of variance (ANOVA) or ANOVA of Kruskal-
Wallis as well as post hoc tests were applied. The Brown-
Forsyth's test was used to determine the homogeneity of
variance. Depending on type of experiment groups con-
sisted of 5–15 mice. The results are presented as mean or
median values and were regarded to be significant when P
< 0.05. Only significant and relevant comparisons
described in the Results section were shown. The name of
groups in the text and figure legends are designated as fol-
lows: CP+P+B+  (mice treated with: cyclophosphamide,
phages, and bacteria, respectively), CP+P-B+ (mice repre-
sent a group of animals pretreated with CP, infected with
bacteria but not given phages).
Results
Effect of bacteriophages on the clearance of S. aureus in 
organs of infected mice, serum IL-6 and TNF-α levels and 
titer of anti-S. aureus agglutinis
Mice were treated with CP, bacteriophages and infected
with bacteria as described in the Materials and Methods.
Control mice received no phages. 24 h after the infection
the bacteria numbers were enumerated in spleens, livers
and kidneys. Mice not treated with CP served as addi-
tional controls. The results shown in Figure 1 indicate that
highly elevated CFU numbers in CP-treated mice (CP+P-
B+) were lowered by the application of phages (CP+P+B+
mice) to the values observed in mice not subjected to CP
treatment (CP-P-B+ group).
The elevated IL-6 concentrations at 24 h after infection in
CP-treated (CP+P-B+) mice (4427 pg/ml versus 80 pg/ml in
control CP-P-B+ mice) were significantly lowered (P  =
0.0064) upon phage application (593 pg/ml) (Figure 2A).
Similarly, elevated TNF-α concentrations in CP-treated
mice (647 versus 170 pg/ml in control CP-P-B+ mice) were
significantly (P = 0.0301) decreased by the administration
of phages (264 pg/ml) (Figure 2B).
Effects of bacteriophages on cell composition in 
circulating blood and bone marrow
In order to evaluate effects of phage application on contri-
bution of cells involved in non specific antimicrobial
defense of CP-immunocompromised and S. aureus-
infected mice, we determined alterations in the cell com-
position of the circulating blood and bone marrow. Alter-
ations in the cell composition of the circulating blood on
day 5 in relation to CP treatment, 24 h following infection
and administration of phages, are presented in Figure 3.
Although in infected, not CP-treated mice, the changes in
the blood cell composition induced by phages were not
significant, we found them more profound in CP-treated
mice. First, in CP+P-B+  mice, apart from mature neu-
trophils, a fraction of immature neutrophils (bands) and
more immature cells (undifferentiated cells, myelocytes,
metamyelocytes and lymphoblasts) appeared, although
on day 4 following CP administration, just before infec-
tion, such cells were virtually not existing in the circula-BMC Microbiology 2009, 9:169 http://www.biomedcentral.com/1471-2180/9/169
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tion. Secondly, the administration of phages (CP+P-B+
versus CP+P+B+ group) significantly enlarged the content of
band forms (P = 0.0261).
The alterations in the bone marrow cell type composition
of mice from the same experiment are presented in Figure
4. The infection of control mice (CP-P-B+ versus CP-P-B-)
led to an increase of the segments content (P = 0.0001)
and co-administration of phages (CP-P+B+ group) mark-
edly increased the percentage of myelocytes (P = 0.0016)
and metamyelocytes (P  = 0.0000). In CP-treated and
infected mice (CP+P-B+) there was a deficit of bands and
no segments were present, however application of phages
in these mice (CP+P+B+ group) led to a significant (a two-
fold) mobilization of myelocytes (P = 0.0068) and bands
(P = 0.0495). Interestingly, the phages alone (CP-P+B-)
increased (P = 0.0000) the content of segments in control,
not infected mice (CP-P-B-). Other changes following
phage administration were not significant.
Effects of the phages on generation of the humoral 
response to S. aureus and to sheep erythrocytes
A possibility existed that phages, beside their direct, pro-
tective role during infection, may stimulate generation of
specific immune response against bacteria. Figure 5 shows
the effects of phage administration on the agglutinin level
in mouse sera taken 21 days following intraperitoneal
immunization of mice with 5 × 106 of S. aureus (for details
see Materials and Methods). The results revealed a strong
up-regulation (P  = 0.0001) of anti-S. aureus  agglutinin
titer in CP and phage-treated mice (CP+P+B+) in compari-
son with a respective control (CP-treated mice) (CP+P-B+
group). The analogous effect of phages in mice not treated
with CP was minor (CP-P+B+ versus CP-P-B+ group). The
phages also enhanced (not significantly), the titer of
hemagglutinins to SRBC in CP-treated and infected mice
(data not shown).
Discussion
The results presented in this report demonstrated not only
efficient removal of the bacterial load in infected mice vir-
tually devoid of major functional phagocytes, by prophy-
lactic administration of specific phages, but also revealed
accompanying, beneficial effects on the immune system,
mediated by S. aureus phage preparation in the described
model. It appeared that application of phages in infected
mice may accelerate renewal of cells depleted by CP treat-
ment, both of the myelocytic and lymphocytic lineages.
The first type of cells has significance in the first-line
defense against bacteria as phagocytes and the latter dif-
ferentiate to mature, immunocompetent cells, giving rise
to adaptive, antigen-specific immune response.
Protective effect of A5/L phages on S. aureus infected mice  pretreated with cyclophosphamide Figure 1
Protective effect of A5/L phages on S. aureus infected 
mice pretreated with cyclophosphamide. A: spleen, B: 
liver, C: kidney. Mice were given CP (350 mg/kg b.w.). After 
four days A5/L phages (106) were administered 30 minutes 
before infection of mice with 5 × 106 of S. aureus. 24 h later 
the CFU were enumerated in the organs. The number of 
mice per group: n = 20. Statistics: A: CP-P-B+ vs CP+P-B+ P = 
0.0004; CP+P-B+ vs CP+P+B+ P = 0.0169 (ANOVA of Kruskal-
Wallis; P = 0.0000); B: CP-P-B+ vs CP+P-B+ P = 0.0004; CP+P-
B+ vs CP+P+B+ P = 0.0009 (ANOVA of Kruskal-Wallis; P = 
0.0000); C: CP-P-B+ vs CP+P-B+ P = 0.0001; CP+P-B+ vs 
CP+P+B+ P = 0.0370 (ANOVA of Kruskal-Wallis; P = 0.0000).
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It is conceivable that the stimulation of hematopoiesis by
phages is initiated by destruction of bacterial walls and
release of bacterial antigens acting as adjuvants for the
immune system. The stimulatory effects of different bacte-
rial antigens on hematopoiesis in CP-immunosuppressed
mice were reported by others [33,34]. The increased stim-
ulation of hematopoiesis in infected, phage-treated
(CP+P+B+) mice versus infected (CP+P-B+) mice or mice
treated only with phages (CP+P+B-), found in this study,
supports such a notion. In infected mice not treated with
CP, the phages elevated the percentage of mature neu-
trophils (segments) (CP-P+B+  versus  CP-P-B+  mice),
although not significantly. That phenomenon could rep-
resent an additional output of mature neutrophils from
the bone marrow reservoir which is particularly large in
rodents [35]. The infection of CP-treated mice (CP+P-B+
group) resulted in a characteristic change in the blood pic-
ture with appearance of immature and mature neu-
trophils as well as more immature cells from myelo- and
lymphocytic lineages. The proportion of these cell types,
including a small contribution of eosinophils and mono-
cytes, significantly increased in mice treated additionally
with phages (from 40.4 to 70.2%) (Figure 3). The effective
killing of bacteria in the investigated organs, particularly
in the liver, where most of the killing takes place [36],
probably resulted from the increased number of phago-
cytes, as shown in this work, although we assume that a
contribution of phages in that process is the major one.
The bone marrow picture in normal mice showed a signif-
icant increase of the mature neutrophils content after
infection (CP-P-B+ group), with a reduction in these cells
upon phage application that suggests an accelerated
export of neutrophils into periphery. The loss of neu-
trophils in the bone marrow was, in this case, compen-
sated by an enlargement of the metamyelocyte pool
(Figure 4). Interestingly, the application of phages alone
(CP-P+B- mice) led also to some increase of the neutrophil
cell content. However, it cannot be excluded that even
well-purified phage preparations used in our experiments
still contain some components of bacterial cells, which
could contribute to the induction of myelopoiesis.
Although the administration of CP (CP+P-B- mice) caused
an anticipated profound loss of the neutrophil cell line-
age, the infection (CP+P-B+ mice) enlarged the fractions of
myelocytes and metamyelocytes. The administration of
phages (CP+P+B+ mice), however, doubled the proportion
of myelocytes (from 12.4 to 23.4%) and bands (from 4.0
to 9.8%). The significant increase of the myelocyte pool in
the bone marrow suggests that phages recruit this cell type
from more immature precursors. In addition, phage prep-
arations apparently support the transition of metamyelo-
cytes to band forms (Figure 4). Taking these observations
together, we may conclude that phages in infected, CP-
immunosuppressed mice act at various stages of the mye-
loid cells differentiation, promoting both the recruitment
of the immature neutrophil cell types from their precur-
sors in the bone marrow and triggering more rapid output
of mature functional neutrophils into periphery.
We can not exclude involvement of other cells capable of
removing bacteria from the circulation, which could be
spared following CP administration such as monocytes
and macrophages residing in the peritoneal cavity and
organs of the reticuloendothelial system, in particular
Kupffer cells [36,37]. Nevertheless, the role of Kupffer
Effects of A5/L phages on IL-6 and TNF-α serum levels in  cyclophosphamide-treated and S. aureus-infected mice Figure 2
Effects of A5/L phages on IL-6 and TNF-α serum lev-
els in cyclophosphamide-treated and S. aureus-
infected mice. A: IL-6, B: TNF-α. Some mice from the 
experiment described in Figure 1 were bled for cytokine 
determination at 24 h following infection. The number of 
mice per group: n = 5. Statistics: A: CP-P-B+ vs CP+P-B+ P = 
0.0023; CP+P-B+ vs CP+P+B+ P = 0.0064 (ANOVA; P = 
0.0009); B: CP-P-B+ vs CP+P-B+ P = 0.0065; CP+P-B+ vs 
CP+P+B+ P = 0.0301 (ANOVA; P = 0.0028).
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cells in the process of bacteria clearance seems to be aux-
iliary for neutrophils [37] which are regarded as the major
phagocyte cell type.
Although we have collected, in the past, observations
regarding acquisition of specific immunity by patients fol-
lowing successful phage therapy, no scientific documenta-
tion exists to support such findings. In this study we
showed that administration of specific phages during
experimental infection, in particular in CP-treated mice,
led to a higher titer of S. aureus serum agglutinins in com-
parison with respective controls (Figure 5). That phenom-
enon was accompanied by the appearance of
lymphoblasts in circulation indicating that the phages
may elicit lymphopoiesis in the bone marrow. Although
CP is cytotoxic, particularly for B cells [38], it spares stem
cells [39] which may serve as a source of a new generation
of immunocompetent T and B cells. Because of high tox-
icity of CP in relation to B cells we applied in this experi-
ment a somewhat lower (200 mg/kg b.w.) dose of the
drug still, however, able to significantly suppress the
humoral immune response [40]. The CP-treated mice
were also able to mount an increased, specific immune
response to an unrelated antigen SRBC. That phenome-
non supported our assumption that the increase of
immune system potential was a consequence of a
bystander (adjuvant) effect of bacterial destruction by
phages.
Neutropenic mice display elevated cytokine levels after
infection [41] that was also confirmed in this study. The
Effects of A5/L phages on the circulating blood cell composi- tion in cyclophosphamide-treated and S. aureus-infected mice Figure 3
Effects of A5/L phages on the circulating blood cell 
composition in cyclophosphamide-treated and S. 
aureus-infected mice. B – bands, S – segments, E – eosi-
nophils, L – lymphocytes, M – monocytes; I – immature 
forms. Mice were given CP (350 mg/kg b.w.). After four days 
1 × 106 A5/L phages and 5 × 106 S. aureus were administered. 
Samples of blood were taken on day 0, just before adminis-
tration of CP (Control), 4 days after administration of CP, 
just before administration of phages and bacteria (day 4) and 
at 24 h following infection (day 5). The results are presented 
as the mean value of 5 mice per group. Statistics (day 5): 
Bands: CP+P-B+ vs CP+P+B+ P = 0.0261 (ANOVA; P = 
0.0000); Segments: CP-P-B+ vs CP+P-B+ P = 0.0003; CP+P-B- 
vs CP+P-B+ P = 0.0489 (ANOVA; P = 0.0000); Eosinophils: 
all crucial comparisons NS (ANOVA); Lymphocytes: CP+P-
B+ vs CP+P+B+ P = 0.0003; CP+P-B- vs CP+P-B+ P = 0.0042 
(ANOVA; P = 0.0000); Monocytes: all crucial comparisons 
NS (ANOVA); Immature forms: CP-P-B+ vs CP+P-B+ P = 
0.0498 (ANOVA; P = 0.0000).
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Effects of A5/L phages on the bone marrow cell composition  in cyclophosphamide-treated and S. aureus-infected mice Figure 4
Effects of A5/L phages on the bone marrow cell com-
position in cyclophosphamide-treated and S. aureus-
infected mice. S – segments, B – bands, Me – metamyelo-
cytes, My – myelocytes, O – other. Mice were given CP (350 
mg/kg b.w.). After four days 1 × 106 A5/L phages and 5 × 106 
S. aureus were administered. The bone marrow was isolated 
on day 0, just before administration of CP (Control) and at 
24 h following infection (day 5). The results are presented as 
the mean value of 5 mice per group. Statistics (day 5): Seg-
ments: CP-P-B+ vs CP+P-B+ P = 0.0001 (ANOVA; P = 
0.0000); Bands: CP-P-B+ vs CP+P-B+ P = 0.0009; CP+P-B+ vs 
CP+P+B+ P = 0.0495 (ANOVA; P = 0.0000); Metamyelo-
cytes: CP-P-B+ vs CP-P+B+ P = 0.0003 (ANOVA; P = 0.0000); 
Myelocytes: CP+P-B+ vs CP+P+B+ P = 0.0062 (ANOVA; P = 
0.0000); Other: CP-P-B+ vs CP+P-B+ P = 0.0003 (ANOVA;P = 
0.0000). Statistics (day 0 vs day 5): Segments: CP-P-B- vs CP-
P-B+ P = 0.0001; CP-P-B- vs CP-P+B- P = 0.0000 (ANOVA); 
Metamyelocytes: CP-P-B- vs CP-P+B+ P = 0.0000 (ANOVA); 
Myelocytes: CP-P-B- vs CP-P+B+ P = 0.0016 (ANOVA).
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inhibitory effects of phages on bacterial CFU numbers in
CP-treated and infected mice (CP+P+B+ group) were asso-
ciated with diminished serum levels of pro-inflammatory
cytokines. This phenomenon could be interpreted as a
profoundly decreased necessity to ingest bacteria by
phagocytes due to removal (lysis) of bacteria by phages. In
such a case release of proinflammatory cytokines which
occurs upon phagocytosis [42] would be diminished. The
down-regulatory effects of phages on the levels of pro-
inflammatory cytokines (particularly TNF-α) during bac-
terial infection (Figure 2), are in contrast to apparently
harmful, increased production of TNF-α during infection
induced by antibiotics [43-45]. Anti-TNF-α antibody can
reduce mortality of mice during antibiotic-induced TNF-α
release during infection [45], providing a proof for the
lethal effects of TNF-α. In the case of S. aureus, beta-lactam
antibiotics increased release of TNF-α in culture of mouse
peritoneal macrophages and the inducing factor was iden-
tified as protein A [44]. It is, therefore, likely that the lytic
action of A5/L bacteriophages leads to a much lesser expo-
sure of bacterial cell components to cells of the immune
system.
Administration of phages shortly before infection is a lim-
itation of this model since it does not reflect a therapeuti-
cal approach. We intend to extend the studies on
immunocompromised mice using a delayed phage appli-
cation.
Conclusion
In summary, this is to our knowledge the first study in a
mouse experimental model showing that prophylactic
phage administration proved both safe to the immuno-
suppressed mice and seemed to serve as immune-function
replacement role. The mobilization of myelopoiesis and
stimulation of the specific, protective antibody response
was a basis for the successful application of phages in
these mice. These results suggest not only safety but also
beneficial effects of phage therapy on the immune status
of immunosuppressed patients.
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